[Hyperfractionated irradiation of non-small cell bronchial cancer. Final results of a Phase II study].
The study was performed for the evaluation of hyperfractionated radiotherapy in the treatment of non-small-cell lung cancer. From radiobiological data we expected that the twice daily irradiation with reduced single dose should result in a better sparing of the slowly proliferating healthy lung tissue without any loss in the tumoricidal effect. 34 patients were treated conventionally with 30 daily fractions of 2.0 Gy over six weeks and another 34 patients twice daily with 1.3 Gy over five weeks to a total dose of 65 Gy. The interval between two fractions lasted at least six hours. Life table (Kaplan-Meier estimate) indicated no contrast between the therapy schedules. The treatment groups did not differ in local response of the primary, progression-free interval and occurrence of distant metastases, the hyperfractionated schedule was very well tolerated. Comparison of the posttreatment quality of life showed a better course after the hyperfractionated regimen, without reaching a level of significance.
Berberich
W
W
Abteilung für Strahlentherapie, Radiologische Universitätsklinik, Homburg/Saar.
Bier
B
B
Schnabel
K
K
Schlimmer
P
P
D000230:Adenocarcinoma / Q000532:radiotherapy*; D002283:Carcinoma, Bronchogenic / Q000532:radiotherapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage